Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer

Amir Goldkorn, Benjamin Ely, David I. Quinn, Catherine M. Tangen, Louis M. Fink, Tong Xu, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael A. Carducci, J. Paul Monk, Ram Datar, Mark Garzotto, Philip C. Mack, Primo Lara, Celestia S. Higano, Maha Hussain, Ian Murchie Thompson, Richard J Cote, Nicholas J. Vogelzang

Research output: Contribution to journalArticle

171 Scopus citations
Original languageEnglish
Pages (from-to)1136-1142
Number of pages7
JournalJournal of Clinical Oncology
Volume32
Issue number11
DOIs
StatePublished - Apr 10 2014

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Goldkorn, A., Ely, B., Quinn, D. I., Tangen, C. M., Fink, L. M., Xu, T., Twardowski, P., Van Veldhuizen, P. J., Agarwal, N., Carducci, M. A., Monk, J. P., Datar, R., Garzotto, M., Mack, P. C., Lara, P., Higano, C. S., Hussain, M., Thompson, I. M., Cote, R. J., & Vogelzang, N. J. (2014). Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 32(11), 1136-1142. https://doi.org/10.1200/JCO.2013.51.7417